Free Trial

Precipio Q4 2024 Earnings Report

Precipio logo
$5.27 +0.12 (+2.33%)
As of 03:48 PM Eastern

Precipio EPS Results

Actual EPS
-$0.23
Consensus EPS
$0.74
Beat/Miss
Missed by -$0.97
One Year Ago EPS
N/A

Precipio Revenue Results

Actual Revenue
$5.45 million
Expected Revenue
$8.01 million
Beat/Miss
Missed by -$2.56 million
YoY Revenue Growth
N/A

Precipio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Precipio Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Precipio Reports Positive Q4 Financial Results
See More Precipio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email.

About Precipio

Precipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

View Precipio Profile

More Earnings Resources from MarketBeat